Dr. Daniel Richard Reed, MD

Dr. Reed practices at Emily Couric Clinical Cancer Center in Charlottesville, Virginia.

Dr. Reed's NPI, 1578982690, was assigned on April 16, 2014. Dr. Reed graduated from Drexel University College of Medicine in 2014. Dr. Reed holds Virginia license 0101277698.

Dr. Reed's primary practice is Emily Couric Clinical Cancer Center, at 1240 Lee St,, Charlottesville, VA 22903. The practice phone is (434) 243-4704.

Dr. Reed's primary practice is Emily Couric Clinical Cancer Center in Charlottesville, Virginia. Dr. Reed is also affiliated with University Medical Center. The medical group on file is UVA Physicians Group. Dmand AI also links Dr. Reed to 4 more hospitals and 1 group practice or clinic, each named with a free account. Dr. Reed's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Reed practices, 7 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Reed's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dmand AI has Dr. Reed's licenses on file in 2 states: Virginia and North Carolina.

CMS data shows 429 Medicare services from Dr. Reed across 8 procedure codes in 2024, for 140 Medicare patients. Medicare paid $33,709 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 140 Medicare patients who saw Dr. Reed in 2024. The largest group is 65 to 74, with 69 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.45, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Reed's median patient age at 67, with 45% women.

In 2024, Dr. Reed wrote 341 Medicare Part D claims for 43 patients. 64% of them were for generic drugs. CMS names the drug for 231 of them, across 10 drugs with 11 or more claims each, at $489,355 in total drug cost. In 2023, CMS named 81 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Reed for performance year 2024, reported as part of a group. CMS lists Dr. Reed as offering telehealth.

Dmand AI links 19 papers to Dr. Reed, published from 2019 to 2025. 2022 was the busiest year, with 4. The most frequent topics are Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma and Antibodies, Bispecific. Dr. Reed has published most often in Curr Hematol Malig Rep. Dr. Reed's most frequent co-authors are Michael K. Keng, MD, Ramey Zaki Elsarrag, MD and Lorenzo Falchi, MD.

Dmand AI links Dr. Reed to 3 clinical trials, 3 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Leukemia, Myeloid and Myelodysplastic Syndromes. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 11 general payments to Dr. Reed from 9 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 80% of the total. Taiho Oncology, Inc. paid the most, $2,463.

Dr. Reed graduated from Drexel University College of Medicine in 2014.